Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Trial Profile

Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms KEYNOTE-001
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Mar 2018 Planned End Date changed from 2 Jul 2018 to 8 Oct 2018.
    • 28 Dec 2017 Results assessing baseline characteristics and long-term follow-up in melanoma patients who experienced complete response with pembrolizumab (n=105) published in the Journal of Clinical Oncology
    • 18 Oct 2017 Results (n=97) of retrospective analysis of patients treated on this trial at UCLA, presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top